Anti-diabetic treatment regulates pro-fibrotic TGF-β serum levels in type 2 diabetics

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Pscherer, Stefan ^a   Freude, Thomas ^b   Forst, Thomas ^c   Nussler, Andreas K ^b   Braun, Karl F ^d   Ehnert, Sabrina ^b  

^a Klinikum Traunstein   (Germany)

^b Berufsgenossenschaftlichen Unfallklinik Tubingen   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Diabetes mellitus type 2; Glucose; Insulin; Proinsulin; TGF

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; INSULIN; INSULIN GLARGINE; METFORMIN; PROINSULIN; SULFONYLUREA; TRANSFORMING GROWTH FACTOR BETA;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EXPLORATORY RESEARCH; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TEST MEAL;

EID: 84883175084     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-48     Document Type: Article

References (17)

1. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Wild S, Roglic G, Green A, Sicree R, King H, Diabetes Care 2004 27 1047 1053 10.2337/diacare.27.5.1047 15111519
2. Standards of medical care in diabetes - 2013. Diabetes Care 2013 36 1 11 66 23264422
3. Inflammation in diabetic nephropathy. Lim AK, Tesch GH, Mediators Inflamm 2012 2012 146154 22969168
4. L-carnosine inhibits high-glucose-mediated matrix accumulation in human mesangial cells by interfering with TGF-beta production and signalling. Koppel H, Riedl E, Braunagel M, Sauerhoefer S, Ehnert S, Godoy P, Sternik P, Dooley S, Yard BA, Nephrol Dial Transplant 2011 26 3852 3858 10.1093/ndt/gfr324 21750159
5. In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment. Pscherer S, Larbig M, von Stritsky B, Pfutzner A, Forst T, J Diabetes Sci Technol 2012 6 634 640 22768894
6. Hyperinsulinemia reduces osteoblast activity in vitro via upregulation of TGF-beta. Freude T, Braun KF, Haug A, Pscherer S, Stockle U, Nussler AK, Ehnert S, J Mol Med (Berl) 2012 90 1257 1266 10.1007/s00109-012-0948-2
7. Highly sensitive and specific bioassay for measuring bioactive TGF-beta. Tesseur I, Zou K, Berber E, Zhang H, Wyss-Coray T, BMC Cell Biol 2006 7 15 10.1186/1471-2121-7-15 16549026
8. Transforming growth factor-beta: a general review. Lawrence DA, Eur Cytokine Netw 1996 7 363 374 8954178
9. TGF-beta signal transduction. Massague J, Annu Rev Biochem 1998 67 753 791 10.1146/annurev.biochem.67.1.753 9759503
10. Roles of TGF-beta in hepatic fibrosis. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S, Front Biosci 2002 7 793 807 10.2741/gressner 11897555
11. Biphasic patterns of peripheral insulin and glucose levels after lunch in normal subjects. Robbins DC, Jaspan J, Vasquez B, Van Cauter E, Diabetes Care 1987 10 293 299 10.2337/diacare.10.3.293 3297577
12. Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells. Cortes P, Riser BL, Asano K, Rodriguez-Barbero A, Narins RG, Yee J, Kidney Int 1998 54 1985 1998 10.1046/j.1523-1755.1998.00207.x 9853263
13. Glibenclamide prevents increased extracellular matrix formation induced by high glucose concentration in mesangial cells. Giannico G, Cortes P, Baccora MH, Hassett C, Taube DW, Yee J, Am J Physiol Renal Physiol 2007 292 57 65 16896180
14. Glibenclamide induces collagen IV catabolism in high glucose-stimulated mesangial cells. Zhu L, Cortes P, Hassett C, Taube DW, Yee J, Exp Diabetes Res 2012 2012 183535 23008698
15. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. Lenski M, Kazakov A, Marx N, Bohm M, Laufs U, J Mol Cell Cardiol 2011 51 906 918 10.1016/j.yjmcc.2011.08.001 21871459
16. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS, J Pharmacol Exp Ther 2012 340 248 255 10.1124/jpet.111.186866 22025647
17. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A, Nat Med 1995 1 74 79 10.1038/nm0195-74 7584958